2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Hepatocellular
9
Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Prostatic Neoplasms
4
Melanoma
4
Breast Neoplasms
4
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Head and Neck Neoplasms
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Pleural Effusion, Malignant
2
Mesothelioma, Malignant
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rare Malignant Neoplasm
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Nephrotic Syndrome
1
Neoplasms, Plasma Cell
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Interventions
Pharmaceutical Preparations
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
All Solid Tumors
×
Pharmaceutical Preparations
×
Clear all
NCT01711398
2015-02-12
IP N02
Elro Pharma
Phase 1/2
Completed
15 enrolled